Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOCYTE AMI-3 phase 3 trial of intravenous FDY-5301 in anterior STEMI undergoing primary PCI
MOH_2022-03-07_010658Phase 3Completed
- Sponsor
- Faraday Pharmaceuticals
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI) comparing FDY-5301 with Matching placebo (2 arms). Primary endpoints: Primary composite endpoint, Cardiovascular death and 1 more. Started Jan 2022; status: completed.
02
Drugs
Sodium iodide
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2022-03-07_010658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-07_010658.